<div id="readability-page-1"><div> (RTTNews) - Werewolf Therapeutics Inc. (HOWL), a biopharmaceutical company, on Thursday announced the first quarter financial results. The company specializes in developing conditionally activated therapies that stimulate the body's immune system to treat cancer and immune-mediated diseases. It has developed a proprietary PREDATOR platform, with to design conditionally activated molecules which stimulate the adaptive and innate immune systems to target malignancies. The INDUKINE molecules are activated in the tumor microenvironment, and INDUCER molecules have been developed to target ovarian and prostate cancers. Q1 2026: The company reported a net loss of $13.53 million, or $0.28 per share in Q1 2026, while in the same period of 2025 the net loss was $18.09 million, or $0.40 per share. Research and development expenses (R&amp;D) were $8.18 million, compared to $13.12 million in the previous year. Cash, cash equivalents, and marketable securities on March 31, 2026, amounted to $46.50 million. Business Updates: The company stated that it had entered into an asset purchase agreement with Jazz Pharmaceuticals Ireland Limited. Jazz previously licensed JZP898, an IFNa program, and has now acquired development and commercialization rights globally. HOWL closed Thursday at $0.62, down 4.64%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. </div></div>

HOWL

JAZZ

IBBQ

Werewolf Therapeutics Inc. reported a Q1 2026 net loss of $13.53 million, improving from a loss of $18.09 million in Q1 2025. R&D expenses decreased to $8.18 million from $13.12 million. The company has $46.50 million in cash and equivalents. Additionally, Werewolf entered an asset purchase agreement with Jazz Pharmaceuticals for global rights to JZP898. The stock closed at $0.62, down 4.64%.

nasdaq

Werewolf Therapeutics

Jazz Pharma

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Nasdaq

Werewolf Reports Q1 Loss Of $13 Mln, Highlights Asset Purchase Agreement With Jazz